Abbott (NYSE:ABT) announced today that it received FDA approval for the use of its Patient Controller app on compatible Apple smartphone devices.
The company’s Patient Controller app offers management tools for patients with implanted neuromodulation devices to treat conditions such as chronic pain or movement disorders. Now, with the latest approval from the FDA, it’s possible to manage an Abbott neuromodulation directly from a personal smartphone.
According to a news release, the approval removes any need for people to carry a separate patient programmer device, streamlining the patient experience and integrating therapy management into everyday life.
Abbott Park, Ill.-based Abbott said the app will be integrated into its broader NeuroSphere Digital Care connected care management platform which became available in May. Other compatibilities for the system include neuromodulation technologies like Abbott’s Infinity DBS system, Proclaim XR SCS system and Proclaim DRG neurostimulation system.
The company said the Patient Controller app with personalized therapy access will be made available in the coming weeks.
“Patients are seeking digital options to better engage with their healthcare providers and manage their chronic conditions remotely – and this has never been more evident than in today’s pandemic where virtual care is necessary,” Abbott VP of neuromodulation Keith Boettiger said in the release. “With the continuing rise in interest and demand for these technologies, Abbott, as a pioneer in patient-centric neuromodulation technology, is advancing the field of digital health to deliver on the promise of digital care.
“The approval of Abbott’s Patient Controller app with personalized access to therapy is a landmark event, as we are now able to provide patients a way to access personalized therapy from a compatible and secure iOS device so that people can live their lives and seamlessly manage conditions like chronic pain and movement disorders.”
